In May 2007, Amgen Inc (Amgen) has received disappointing news from the European Medicines Agency (EMEA), that its drug Vectibix, developed to deal with metastatic colorectal cancer who had been rejected. This was especially surprising, given that the news like a rival drug was approved a few years ago. In addition, Vectibix was approved as the Food and Drug Administration in 2006. In additional tests, Amgen learned that Vectibix is only at 60% of the population that has a specific marker gene. In view of this development, the strategy should be Vectibix Amgen around in Europe and the United States? "Hide
by Richard G. Hamermesh, Raju Kucherlapati, Rachel Gordon Source: Harvard Business School 8 pages. Publication Date: 06 November 2009. Prod. #: 810066-PDF-ENG
Related Case Solutions & Analyses:
Savage Beast (A1)
ATH MicroTechnologies Inc. (E)
Palm (C): 2005
Airbus vs. Boeing (C): Developments from 1996 to 1999
Role of the Internet in Physician-Patient Relationships: The Issue of Trust
Northern Forest (F): Policy Alternatives
Charles Schwab in 2002 Spreadsheet Exercise
Saras Options
Fsas: Fujitsu Support and Service Inc.
Note on the FDReview Process for Medical Devices
